 | • レポートコード：GIR-107A12166 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、慢性閉塞性肺疾患（COPD）のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。慢性閉塞性肺疾患（COPD）の種類別市場規模（短時間作用型気管支拡張薬、コルチコステロイド、メチルキサンチン、長時間作用型気管支拡張薬、ホスホジエステラーゼ-4阻害薬、その他）、用途別市場規模（病院、クリニック）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・慢性閉塞性肺疾患（COPD）の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：GSK、Pfizer、Merck、Novartis、AstraZeneca、Boehringer Ingelheim、Teva Pharmaceuticals、Ario Pharma、Roche、Ache、Almirall、Aquinox Pharmaceuticals、Asmacure、Astellas Pharma ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：短時間作用型気管支拡張薬、コルチコステロイド、メチルキサンチン、長時間作用型気管支拡張薬、ホスホジエステラーゼ-4阻害薬、その他 ・用途別分析2016年-2026年：病院、クリニック ・慢性閉塞性肺疾患（COPD）の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・慢性閉塞性肺疾患（COPD）のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・慢性閉塞性肺疾患（COPD）のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・慢性閉塞性肺疾患（COPD）の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・慢性閉塞性肺疾患（COPD）の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Chronic Obstructive Pulmonary Disorder (COPD) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Chronic Obstructive Pulmonary Disorder (COPD) size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Chronic Obstructive Pulmonary Disorder (COPD) market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Chronic Obstructive Pulmonary Disorder (COPD) market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Short-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
Others
Market segment by Application, can be divided into
Hospital
Clinic
Market segment by players, this report covers
GSK
Pfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
Asmacure
Astellas Pharma
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Chronic Obstructive Pulmonary Disorder (COPD) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Chronic Obstructive Pulmonary Disorder (COPD), with revenue, gross margin and global market share of Chronic Obstructive Pulmonary Disorder (COPD) from 2019 to 2021.
Chapter 3, the Chronic Obstructive Pulmonary Disorder (COPD) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Chronic Obstructive Pulmonary Disorder (COPD) market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Chronic Obstructive Pulmonary Disorder (COPD) research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Chronic Obstructive Pulmonary Disorder (COPD)
1.2 Classification of Chronic Obstructive Pulmonary Disorder (COPD) by Type
1.2.1 Overview: Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type in 2020
1.2.3 Short-Acting Bronchodilators
1.2.4 Corticosteroids
1.2.5 Methylxanthines
1.2.6 Long-Acting Bronchodilators
1.2.7 Phosphodiesterase-4 Inhibitors
1.2.8 Others
1.3 Global Chronic Obstructive Pulmonary Disorder (COPD) Market by Application
1.3.1 Overview: Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size & Forecast
1.5 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast by Region
1.5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region, (2016-2021)
1.5.3 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Prospect (2016-2026)
1.5.4 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Prospect (2016-2026)
1.5.6 South America Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers
1.6.2 Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints
1.6.3 Chronic Obstructive Pulmonary Disorder (COPD) Trends Analysis
2 Company Profiles
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business
2.1.3 GSK Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.1.4 GSK Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 GSK Recent Developments and Future Plans
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.2.4 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Pfizer Recent Developments and Future Plans
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business
2.3.3 Merck Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.3.4 Merck Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Merck Recent Developments and Future Plans
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.4.4 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Novartis Recent Developments and Future Plans
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.5.4 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 AstraZeneca Recent Developments and Future Plans
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.6.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Boehringer Ingelheim Recent Developments and Future Plans
2.7 Teva Pharmaceuticals
2.7.1 Teva Pharmaceuticals Details
2.7.2 Teva Pharmaceuticals Major Business
2.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.7.4 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Teva Pharmaceuticals Recent Developments and Future Plans
2.8 Ario Pharma
2.8.1 Ario Pharma Details
2.8.2 Ario Pharma Major Business
2.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.8.4 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Ario Pharma Recent Developments and Future Plans
2.9 Roche
2.9.1 Roche Details
2.9.2 Roche Major Business
2.9.3 Roche Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.9.4 Roche Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Roche Recent Developments and Future Plans
2.10 Ache
2.10.1 Ache Details
2.10.2 Ache Major Business
2.10.3 Ache Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.10.4 Ache Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Ache Recent Developments and Future Plans
2.11 Almirall
2.11.1 Almirall Details
2.11.2 Almirall Major Business
2.11.3 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.11.4 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Almirall Recent Developments and Future Plans
2.12 Aquinox Pharmaceuticals
2.12.1 Aquinox Pharmaceuticals Details
2.12.2 Aquinox Pharmaceuticals Major Business
2.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.12.4 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Aquinox Pharmaceuticals Recent Developments and Future Plans
2.13 Asmacure
2.13.1 Asmacure Details
2.13.2 Asmacure Major Business
2.13.3 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.13.4 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Asmacure Recent Developments and Future Plans
2.14 Astellas Pharma
2.14.1 Astellas Pharma Details
2.14.2 Astellas Pharma Major Business
2.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.14.4 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Astellas Pharma Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Chronic Obstructive Pulmonary Disorder (COPD) Players Market Share
3.2.2 Top 10 Chronic Obstructive Pulmonary Disorder (COPD) Players Market Share
3.2.3 Market Competition Trend
3.3 Chronic Obstructive Pulmonary Disorder (COPD) Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Market Share by Type (2016-2021)
4.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application (2016-2021)
5.2 Chronic Obstructive Pulmonary Disorder (COPD) Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2016-2026)
6.2 North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2016-2026)
6.3 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country
6.3.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2016-2026)
6.3.2 United States Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
6.3.3 Canada Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
6.3.4 Mexico Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2016-2026)
7.2 Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2016-2026)
7.3 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country
7.3.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2016-2026)
7.3.2 Germany Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
7.3.3 France Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
7.3.5 Russia Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
7.3.6 Italy Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2016-2026)
8.2 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2016-2026)
8.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region
8.3.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Region (2016-2026)
8.3.2 China Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
8.3.3 Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
8.3.4 South Korea Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
8.3.5 India Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
8.3.7 Australia Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2016-2026)
9.2 South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2016-2026)
9.3 South America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country
9.3.1 South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2016-2026)
9.3.2 Brazil Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
9.3.3 Argentina Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2016-2026)
10.2 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2016-2026)
10.3 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country
10.3.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2016-2026)
10.3.2 Turkey Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
10.3.4 UAE Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Chronic Obstructive Pulmonary Disorder (COPD) Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) by Region (2016-2021)
Table 5. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Region (2021-2026)
Table 6. GSK Corporate Information, Head Office, and Major Competitors
Table 7. GSK Major Business
Table 8. GSK Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 9. GSK Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Pfizer Corporate Information, Head Office, and Major Competitors
Table 11. Pfizer Major Business
Table 12. Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 13. Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Merck Corporate Information, Head Office, and Major Competitors
Table 15. Merck Major Business
Table 16. Merck Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 17. Merck Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Novartis Corporate Information, Head Office, and Major Competitors
Table 19. Novartis Major Business
Table 20. Novartis Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 21. Novartis Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 23. AstraZeneca Major Business
Table 24. AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 25. AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 27. Boehringer Ingelheim Major Business
Table 28. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 29. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Teva Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 31. Teva Pharmaceuticals Major Business
Table 32. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 33. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Ario Pharma Corporate Information, Head Office, and Major Competitors
Table 35. Ario Pharma Major Business
Table 36. Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 37. Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Roche Corporate Information, Head Office, and Major Competitors
Table 39. Roche Major Business
Table 40. Roche Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 41. Roche Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Ache Corporate Information, Head Office, and Major Competitors
Table 43. Ache Major Business
Table 44. Ache Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 45. Ache Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Almirall Corporate Information, Head Office, and Major Competitors
Table 47. Almirall Major Business
Table 48. Almirall Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 49. Almirall Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Aquinox Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 51. Aquinox Pharmaceuticals Major Business
Table 52. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 53. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Asmacure Corporate Information, Head Office, and Major Competitors
Table 55. Asmacure Major Business
Table 56. Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 57. Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Astellas Pharma Corporate Information, Head Office, and Major Competitors
Table 59. Astellas Pharma Major Business
Table 60. Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 61. Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) by Players (2019-2021)
Table 63. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Share by Players (2019-2021)
Table 64. Breakdown of Chronic Obstructive Pulmonary Disorder (COPD) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 65. Chronic Obstructive Pulmonary Disorder (COPD) Players Head Office, Products and Services Provided
Table 66. Chronic Obstructive Pulmonary Disorder (COPD) Mergers & Acquisitions in the Past Five Years
Table 67. Chronic Obstructive Pulmonary Disorder (COPD) New Entrants and Expansion Plans
Table 68. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) by Type (2016-2021)
Table 69. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Share by Type (2016-2021)
Table 70. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Forecast by Type (2021-2026)
Table 71. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2016-2021)
Table 72. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Forecast by Application (2021-2026)
Table 73. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2016-2021) & (USD Million)
Table 74. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2021-2026) & (USD Million)
Table 75. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2016-2021) & (USD Million)
Table 76. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2021-2026) & (USD Million)
Table 77. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2016-2021) & (USD Million)
Table 78. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2021-2026) & (USD Million)
Table 79. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2016-2021) & (USD Million)
Table 80. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2021-2026) & (USD Million)
Table 81. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2016-2021) & (USD Million)
Table 82. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2021-2026) & (USD Million)
Table 83. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2016-2021) & (USD Million)
Table 84. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2021-2026) & (USD Million)
Table 85. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2016-2021) & (USD Million)
Table 86. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2021-2026) & (USD Million)
Table 87. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2016-2021) & (USD Million)
Table 88. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2021-2026) & (USD Million)
Table 89. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Region (2016-2021) & (USD Million)
Table 90. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Region (2021-2026) & (USD Million)
Table 91. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2016-2021) & (USD Million)
Table 92. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2021-2026) & (USD Million)
Table 93. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2016-2021) & (USD Million)
Table 94. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2021-2026) & (USD Million)
Table 95. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2016-2021) & (USD Million)
Table 96. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2021-2026) & (USD Million)
Table 97. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2016-2021) & (USD Million)
Table 98. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2021-2026) & (USD Million)
Table 99. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2016-2021) & (USD Million)
Table 100. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2021-2026) & (USD Million)
Table 101. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2016-2021) & (USD Million)
Table 102. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Chronic Obstructive Pulmonary Disorder (COPD) Picture
Figure 2. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type in 2020
Figure 3. Short-Acting Bronchodilators
Figure 4. Corticosteroids
Figure 5. Methylxanthines
Figure 6. Long-Acting Bronchodilators
Figure 7. Phosphodiesterase-4 Inhibitors
Figure 8. Others
Figure 9. Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application in 2020
Figure 10. Hospital Picture
Figure 11. Clinic Picture
Figure 12. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Region (2016-2026)
Figure 15. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Region in 2020
Figure 16. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers
Figure 22. Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints
Figure 23. Chronic Obstructive Pulmonary Disorder (COPD) Market Trends
Figure 24. GSK Recent Developments and Future Plans
Figure 25. Pfizer Recent Developments and Future Plans
Figure 26. Merck Recent Developments and Future Plans
Figure 27. Novartis Recent Developments and Future Plans
Figure 28. AstraZeneca Recent Developments and Future Plans
Figure 29. Boehringer Ingelheim Recent Developments and Future Plans
Figure 30. Teva Pharmaceuticals Recent Developments and Future Plans
Figure 31. Ario Pharma Recent Developments and Future Plans
Figure 32. Roche Recent Developments and Future Plans
Figure 33. Ache Recent Developments and Future Plans
Figure 34. Almirall Recent Developments and Future Plans
Figure 35. Aquinox Pharmaceuticals Recent Developments and Future Plans
Figure 36. Asmacure Recent Developments and Future Plans
Figure 37. Astellas Pharma Recent Developments and Future Plans
Figure 38. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Share by Players in 2020
Figure 39. Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 40. Global Top 3 Players Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share in 2020
Figure 41. Global Top 10 Players Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share in 2020
Figure 42. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 43. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Share by Type in 2020
Figure 44. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share Forecast by Type (2021-2026)
Figure 45. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Share by Application in 2020
Figure 46. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share Forecast by Application (2021-2026)
Figure 47. North America Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Type (2016-2026)
Figure 48. North America Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Application (2016-2026)
Figure 49. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Country (2016-2026)
Figure 50. United States Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Canada Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Mexico Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Europe Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Type (2016-2026)
Figure 54. Europe Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Application (2016-2026)
Figure 55. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Country (2016-2026)
Figure 56. Germany Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. France Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. United Kingdom Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Russia Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Italy Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Type (2016-2026)
Figure 62. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Application (2016-2026)
Figure 63. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Region (2016-2026)
Figure 64. China Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Japan Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South Korea Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. India Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Australia Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. South America Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Type (2016-2026)
Figure 71. South America Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Application (2016-2026)
Figure 72. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Country (2016-2026)
Figure 73. Brazil Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Argentina Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Middle East and Africa Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Type (2016-2026)
Figure 76. Middle East and Africa Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Application (2016-2026)
Figure 77. Middle East and Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Country (2016-2026)
Figure 78. Turkey Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Saudi Arabia Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. UAE Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Methodology
Figure 82. Research Process and Data Source
COPD薬市場：世界及び中国市場分析・予測（～2024年） COPD Drugs Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global COPD Drugs industry with a focus on the Chinese market. The report provides key statistics on the market status of the COPD Drugs manufacturers and is a valuable sourc…- 世界のCOPD用粘液クリアランス装置市場 2021：企業別、地域別、種類・用途別 The Mucus Clearance Devices for COPD market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trad…
- 世界の自閉症スペクトラム障害診断市場 2021：企業別、地域別、種類・用途別 The Autism Spectrum Disorder Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …
- 医療用酸素濃縮器の世界市場 2019年版：種類別（ポータブル酸素濃縮器、固定酸素濃縮器）、用途別（慢性閉塞性肺疾患（COPD）、喘息、睡眠時無呼吸、その他） Scope of the Report: The worldwide market for Medical Oxygen Concentrators is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Medical Ox…
- COPD遠隔監視システムの世界市場 2019年版：種類別（ポータブル、固定）、用途別（在宅ケア、介護センター、病院ケア） Scope of the Report: The worldwide market for COPD Telemonitoring System is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the COPD Telemon…